Stock Evaluator: Lakewood-Amedex Biotherapeutics, Inc. (LABT)
Lakewood-Amedex Biotherapeutics, Inc. LABT
$0.28
-0.03
-8.71%
October 26, 2026 4:00:00 PM
EST
Volume: 2,742,666
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Financial Summary
| Share Statistics | LABT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $0.7 | $229.7 | 1% |
|
| Shares Out (Mil) | 1.4 | 53.4 | 6% |
|
| Institutional Ownership | 9.5% | 92.9% | 6% |
|
| Float (Mil) | 0.8 | 41.7 | 2% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 4,041 | 520 | 90% |
|
| Price Change (52-week) |
na | 46.5% | na |
|
| Growth | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($44) | 31% |
|
| EPS (TTM) | ($10.200) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($33) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1 | $175 | 4% |
|
| Valuation | LABT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.15 | 2.17 | 3% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LABT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (225.4%) | (47.2%) | 2% |
|
| ROE | (403.2%) | (53.5%) | 2% |
|
| Liabilities to Assets | 12.7% | 29.4% | 8% |
|
| F-Score | 2 | 2 | 7% |
|
Lakewood-Amedex Biotherapeutics, Inc. did not pass any screens on 10/23/2026.
